Financial Performance - The company's revenue for Q1 2025 was ¥272,090,793.91, representing a 16.63% increase compared to ¥233,288,808.06 in the same period last year[5] - Net profit attributable to shareholders was ¥90,471,778.52, a 40.92% increase from ¥64,199,068.03 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥87,223,537.32, up 53.07% from ¥56,981,941.60 in the previous year[5] - Basic and diluted earnings per share were both ¥0.23, a 43.75% increase from ¥0.16 in the previous year[5] - Total operating revenue for the current period reached ¥272,090,793.91, an increase of 16.6% compared to ¥233,288,808.06 in the previous period[20] - Net profit for the current period was ¥90,471,778.52, representing a significant increase of 40.9% from ¥64,199,068.03 in the previous period[21] - The company's profit before tax was ¥101,793,500.12, an increase of 38.3% from ¥73,566,224.34 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities was ¥103,254,852.84, reflecting a 28.14% increase compared to ¥80,577,903.10 in the same period last year[5] - Operating cash flow increased to 103,254,852.84 from 80,577,903.10, a rise of 28.06%[22] - Total cash inflow from operating activities reached 290,859,140.41, compared to 273,690,053.97 in the previous period, marking a 6.25% increase[22] - Cash and cash equivalents at the end of the period decreased to 288,933,634.09 from 323,750,184.55, a drop of 10.76%[23] - The company reported a net increase in cash and cash equivalents of -26,528,201.73, contrasting with a net increase of 122,672,317.88 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,163,512,829.30, a 4.78% increase from ¥2,064,801,711.06 at the end of the previous year[5] - Total liabilities rose to ¥244,665,855.76, compared to ¥221,536,953.20, indicating an increase of 10.4%[18] - The company's total assets increased to ¥2,163,512,829.30 from ¥2,064,801,711.06, marking a growth of 4.8%[18] - Total current assets increased to ¥1,891,421,886.64 from ¥1,788,399,896.77[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,012[12] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.31% of shares, totaling 87,701,616 shares[12] - The total number of shares held by the top ten unrestricted shareholders is 87,701,616, with Forward Investment (Hong Kong) Limited being the largest[13] - The total number of restricted shares at the end of the period is 3,464,606, down from 3,527,230 due to the unlocking of shares[14] - The company has no reported related party relationships or concerted actions among the top shareholders[13] Expenses and Investments - Total operating costs amounted to ¥171,878,070.83, up from ¥167,788,210.58, reflecting a growth of 1.3%[20] - Research and development expenses were ¥41,536,126.88, a decrease of 14.1% from ¥48,363,080.43 in the previous period[20] - The company has a long-term investment of ¥10,497,291.81, down from ¥11,951,810.18[16] - The financial expenses showed a significant improvement, with a net income of -¥10,374,808.85 compared to -¥3,263,353.11 previously[20] Future Plans and Accounting Changes - The company plans to continue its market expansion and product development strategies, although specific details were not disclosed in the provided content[15] - The company plans to adopt new accounting standards starting in 2025, which may impact future financial reporting[24] - The first quarter report was not audited, indicating a preliminary assessment of financial performance[24]

证券代码：300685 证券简称：艾德生物 公告编号：2025-019 厦门艾德生物医药科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 以未来实施 2024 年度权益分配方案时股权登记日的总股本（扣除回购专用证券账 户股份）为基数，向全体股东每 10 股派发现金红利 3 元（含税），预计共派发现金红利 117,918,590.701元（含税），不送红股，不以资本公积金转增股本。 一、审议程序 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"） 于 2025 年 4 月 19 日召开第四届董事会第六次会议及第四届监事会第五次会议， 审议通过了《关于 2024 年度利润分配方案的议案》。本议案尚需提交公司 2024 年度股东大会审议。 二、利润分配方案的基本情况 1、本次利润分配为公司 2024 年度利润分配。 2、根据《公司法》和《公司章程》的有关规定，2024 年提取法定盈余公积 金 21,265,143.33 元。经立信会计师事务所（特殊普通合伙）审计，截至 2024 年 ...

Group 1 - The core viewpoint of the article highlights the financial performance of Aide Biological (300685) in the first quarter of 2025, showing significant growth in both revenue and net profit [1] Group 2 - The company's revenue for Q1 2025 reached 272 million yuan, representing a year-on-year increase of 16.63% [1] - The net profit for the same period was 90.4718 million yuan, reflecting a year-on-year growth of 40.92% [1]

Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include molecular diagnostic reagents for targeted cancer therapy and chemotherapy, which help clinicians develop personalized treatment plans based on the genetic status of cancer patients [2] Financial Performance - For the third quarter of 2024, the company reported a revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of the latest data, the company's rolling price-to-earnings (PE) ratio is 28.56, while the average PE ratio in the medical device industry is 46.48, and the industry median is 31.96 [1][3] - The total market capitalization of the company is approximately 8.997 billion yuan [1] Institutional Holdings - As of the third quarter of 2024, a total of 264 institutions hold shares in the company, including 263 funds and 1 brokerage, with a total holding of 63.719 million shares valued at 1.453 billion yuan [1]

Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include targeted drug molecular diagnostic reagents and chemotherapy drug molecular diagnostic reagents, which are used to assess the genetic status of cancer patients [2] - The company holds multiple qualifications, including "National High-tech Enterprise" and "National Enterprise Technology Center," and has received various awards for its research and development efforts [2] Financial Performance - For the third quarter of 2024, the company reported revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of April 1, the company's stock closed at 23.15 yuan, with a price-to-earnings (PE) ratio of 28.88 times, while the average PE ratio in the medical device industry is 46.46 times [1][3] - The company's total market capitalization is approximately 9.099 billion yuan [1] - In terms of market performance, the company ranked 65th in the industry based on PE ratio [1]

发明专利名称：一种探针及其适用于高通量测序的对目标区域进行富集的方 法 证券代码：300685 证券简称：艾德生物 公告编号：2025-013 厦门艾德生物医药科技股份有限公司 关于取得日本发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于近日收到日本特许厅颁发的发明专利证书。具体情况如下： 专利权人：厦门艾德生物医药科技股份有限公司 上述发明专利为公司自主研发，已在公司相关产品上应用。上述专利的取得 不会对公司近期生产经营产生重大影响，但有利于进一步完善公司知识产权保护 体系，充分发挥自主知识产权优势，促进技术创新，增强公司海外市场竞争力， 提升公司的综合实力。 厦门艾德生物医药科技股份有限公司 董 事 会 2025 年 3 月 10 日 专利号：特许第7641118号 专利类型：发明专利 专利申请日：2018年7月18日 专利权期限：自申请日起二十年 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-012 厦门艾德生物医药科技股份有限公司 关于回购股份注销完成暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"）本次 注销的回购股份数量为5,374,840股，占本次注销前公司总股本的1.35%，本次注销完成 后，公司总股本由398,436,809股变更为393,061,969股。 2、经中国证券登记结算有限责任公司深圳分公司确认，公司本次回购股份注销事 宜已于2025年3月4日办理完成。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 法律法规规定，现就本次回购公司股份注销完成的具体情况公告如下： 一、回购股份的实施情况 公司于 2024 年 2 月 26 日召开 2024 年第一次临时股东大会，审议通过了《关 于以集中竞价交易方式回购公司股份的议案》。根据本次回购方案，公司拟使用 自有资金以集中竞价方式回购股份用于注销并减少公司注册资本；回购资金总额 为不低于人民币 10,000 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-011 厦门艾德生物医药科技股份有限公司 关于回购股份期限届满暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于2024年2月26日召开2024年第一次临时股东大会，审议通过了《关于以集中竞 价交易方式回购公司股份的议案》。根据本次回购方案，公司拟使用自有资金以 集中竞价方式回购股份用于注销并减少公司注册资本；回购资金总额为不低于人 民币10,000万元且不超过人民币20,000万元，具体回购资金金额以回购实施完成 时实际回购的金额为准；回购股份的实施期限为自公司股东大会审议通过本次回 购方案之日起12个月内。具体内容详见公司于2024年2月26日刊登在巨潮资讯网 的《回购报告书》。 截至本公告披露日，公司本次回购股份方案的实施期限已届满，股份回购已 实施完成，现将本次回购的有关事项公告如下： 一、回购股份的实施情况 2024 年 3 月 29 日，公司首次通过回购专用证券账户以集中竞价交易方式实 施回购股份 1 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-010 产品名称：PD-L1抗体试剂（免疫组织化学法） 注册证编号：国械注准20223400313 变更内容：预期用途增加"本试剂盒用于体外定性检测经10%中性缓冲福尔 马 林 固 定 石 蜡 包 埋 （ FFPE ） 胃 / 胃 食 管 交 界 处 腺 癌 （ Gastric Adenocarcinoma/Gastroesophageal Adenocarcinoma，GA/GEA）组织切片中PD-L1 蛋白的表达情况，辅助鉴别可使用舒格利单抗联合化疗治疗的 GA/GEA患者，用 作舒格利单抗联合化疗的伴随诊断。"。 备注：本变更注册文件与"国械注准20223400313"注册证共同使用。 二、对公司的影响及风险提示 厦门艾德生物医药科技股份有限公司 关于公司收到医疗器械变更注册文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"）于近日收到由国 家药品监督管理局颁发的《医疗器械变更注册文件》，公司已完成"PD-L1抗体 试剂（免疫组织化 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-009 厦门艾德生物医药科技股份有限公司 关于回购股份进展的公告 公司回购股份的时间、回购股份数量及集中竞价交易的委托时间段等均符合 《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规定。 1、公司未在下列期间内回购股份： （1）自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于2024年2月26日召开2024年第一次临时股东大会，审议通过了《关于以集中竞 价交易方式回购公司股份的议案》。根据本次回购方案，公司拟使用自有资金以 集中竞价方式回购股份用于注销并减少公司注册资本；回购资金总额为不低于人 民币10,000万元且不超过人民币20,000万元，具体回购资金金额以回购实施完成 时实际回购的金额为准；回购股份的实施期限为自公司股东大会审议通过本次回 购方案之日 ...